{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:50:34Z","timestamp":1780599034621,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sabine D\u00f6rges Stiftung f\u00fcr Krebskranke Kinder und Jugendliche"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5394-x","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T14:05:08Z","timestamp":1551449108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas"],"prefix":"10.1186","volume":"19","author":[{"given":"Anne-Katrin","family":"Hickmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Battke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Bittl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ganslandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Biskup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"D\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"1","key":"5394_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.beha.2011.12.001","volume":"25","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012;25(1):119\u201330.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"5394_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00292-002-0539-z","volume":"23","author":"W Feiden","year":"2002","unstructured":"Feiden W, Milutinovic S. Primary CNS lymphomas. Morphology and diagnosis. Pathologe. 2002;23(4):284\u201391.","journal-title":"Pathologe"},{"issue":"11","key":"5394_CR3","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00701-015-2543-0","volume":"157","author":"IS Verploegh","year":"2015","unstructured":"Verploegh IS, Volovici V, Haitsma IK, Schouten JW, Dirven CM, Kros JM, Dammers R. Contemporary frameless intracranial biopsy techniques: might variation in safety and efficacy be expected? Acta Neurochir. 2015;157(11):2011\u20136 discussion 2016.","journal-title":"Acta Neurochir"},{"issue":"2","key":"5394_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ab.2012.06.018","volume":"433","author":"L Benesova","year":"2013","unstructured":"Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, Levy M, Visokai V, Zavoral M, Minarik M. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013;433(2):227\u201334.","journal-title":"Anal Biochem"},{"key":"5394_CR5","doi-asserted-by":"publisher","unstructured":"Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579-86. https:\/\/doi.org\/10.1200\/JCO.2012.45.2011 . Epub 2014 Jan 21.","DOI":"10.1200\/JCO.2012.45.2011"},{"issue":"8","key":"5394_CR6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1586\/14737159.2013.845088","volume":"13","author":"DM Marzese","year":"2013","unstructured":"Marzese DM, Hirose H, Hoon DS. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013;13(8):827\u201344.","journal-title":"Expert Rev Mol Diagn"},{"issue":"12","key":"5394_CR7","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/0008-5472.CAN-05-4198","volume":"66","author":"K Koyanagi","year":"2006","unstructured":"Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006;66(12):6111\u20137.","journal-title":"Cancer Res"},{"issue":"45","key":"5394_CR8","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5394_CR9","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.22598","volume":"120","author":"M Daniotti","year":"2007","unstructured":"Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007;120(11):2439\u201344.","journal-title":"Int J Cancer"},{"issue":"6","key":"5394_CR10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00401-015-1399-y","volume":"129","author":"MG Best","year":"2015","unstructured":"Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol. 2015;129(6):849\u201365.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"5394_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/07357900500449546","volume":"24","author":"KD Weaver","year":"2006","unstructured":"Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Investig. 2006;24(1):35\u201340.","journal-title":"Cancer Investig"},{"issue":"6","key":"5394_CR12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/neuonc\/nop064","volume":"12","author":"BL Liu","year":"2010","unstructured":"Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, Huo JL, Cheng H. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncology. 2010;12(6):540\u20138.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"5394_CR13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12031-011-9617-0","volume":"46","author":"W Shi","year":"2012","unstructured":"Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, Wu X, Ju S, Chen J. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci. 2012;46(3):470\u20135.","journal-title":"J Mol Neurosci"},{"issue":"2","key":"5394_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0972-6748.62274","volume":"18","author":"A Banerjee","year":"2009","unstructured":"Banerjee A, Chitnis UB, Jadhav SL, Bhawalkar JS, Chaudhury S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009;18(2):127\u201331.","journal-title":"Ind Psychiatry J"},{"issue":"6","key":"5394_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apa.13384","volume":"105","author":"AK Akobeng","year":"2016","unstructured":"Akobeng AK. Understanding type I and type II errors, statistical power and sample size. Acta Paediatr. 2016;105(6):605\u20139.","journal-title":"Acta Paediatr"},{"issue":"1","key":"5394_CR16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12859-017-1728-3","volume":"18","author":"JF Mudge","year":"2017","unstructured":"Mudge JF, Martyniuk CJ, Houlahan JE. Optimal alpha reduces error rates in gene expression studies: a meta-analysis approach. BMC Bioinformatics. 2017;18(1):312.","journal-title":"BMC Bioinformatics"},{"key":"5394_CR17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12859-016-0994-9","volume":"17","author":"R Bi","year":"2016","unstructured":"Bi R, Liu P. Sample size calculation while controlling false discovery rate for differential expression analysis with RNA-sequencing experiments. BMC Bioinformatics. 2016;17:146.","journal-title":"BMC Bioinformatics"},{"key":"5394_CR18","unstructured":"Cosmic - Catalogue of somatic mutations in cancer [ http:\/\/cancer.sanger.ac.uk\/cosmic\/browse\/tissue-in=t&sn=haematopoietic_and_lymphoid_tissue&ss=all&hn=lymphoid_neoplasm . Accessed 14 Apr 2018."},{"key":"5394_CR19","unstructured":"NCBI Gene database [ https:\/\/www.ncbi.nlm.nih.gov\/gene\/5292 ]. Accessed 14 Apr 2018."},{"issue":"5","key":"5394_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1044-579X(02)00058-5","volume":"12","author":"MS Lindstrom","year":"2002","unstructured":"Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol. 2002;12(5):381\u20137.","journal-title":"Semin Cancer Biol"},{"issue":"31","key":"5394_CR21","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1073\/pnas.1511694112","volume":"112","author":"Y Wang","year":"2015","unstructured":"Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5394_CR22","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.2147\/OTT.S102504","volume":"9","author":"J Pinilla-Ibarz","year":"2016","unstructured":"Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016;9:4937\u201357.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"5394_CR23","first-page":"520","volume":"14","author":"B Zhang","year":"2016","unstructured":"Zhang B, Hurvitz S. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clin Adv Hematol Oncol. 2016;14(7):520\u201330.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"13","key":"5394_CR24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cncr.29364","volume":"121","author":"H Kinugasa","year":"2015","unstructured":"Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, Kato H, Matsubara T, Okada H, Yamamoto K. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 2015;121(13):2271\u201380.","journal-title":"Cancer"},{"issue":"7404","key":"5394_CR25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537\u201340.","journal-title":"Nature"},{"issue":"39","key":"5394_CR26","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget"},{"key":"5394_CR27","doi-asserted-by":"publisher","unstructured":"Weller M, Reifenberger G, Tonn JC, Wick W. Gliome: Aktuelle Entwicklungen in der Diagnostik und Therapie. Dtsch Arztebl. 2016;113(6):18. https:\/\/doi.org\/10.3238\/PersOnko\/2016.02.12.04 .","DOI":"10.3238\/PersOnko\/2016.02.12.04"},{"key":"5394_CR28","doi-asserted-by":"publisher","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023\u201331. https:\/\/doi.org\/10.1038\/nbt.2696 . Epub 2013 Oct 20.","DOI":"10.1038\/nbt.2696"},{"key":"5394_CR29","doi-asserted-by":"publisher","unstructured":"Haslem DS, Van Norman SB, Fulde G, Knighton AJ, Belnap T, Butler AM, Rhagunath S, Newman D, Gilbert H, Tudor BP, et al. A retrospective analysis of precision medicine outcomes in patients with advanced Cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract. 2017;13(2):e108-19. https:\/\/doi.org\/10.1200\/JOP.2016.011486 . Epub 2016 Oct 31.","DOI":"10.1200\/JOP.2016.011486"},{"key":"5394_CR30","doi-asserted-by":"publisher","unstructured":"Fontanilles M, Marguet F, Bohers E, Viailly PJ, Dubois S, Bertrand P, Camus V, Mareschal S, Ruminy P, Maingonnat C, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017;8(29):48157\u201368. https:\/\/doi.org\/10.18632\/oncotarget.18325 .","DOI":"10.18632\/oncotarget.18325"},{"issue":"13","key":"5394_CR31","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","volume":"5","author":"A Bruno","year":"2014","unstructured":"Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014;5(13):5065\u201375.","journal-title":"Oncotarget"},{"key":"5394_CR32","doi-asserted-by":"crossref","unstructured":"Todorovic Balint M, Jelicic J, Mihaljevic B, Kostic J, Stanic B, Balint B, Pejanovic N, Lucic B, Tosic N, Marjanovic I, et al. Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses. Int J Mol Sci. 2016;17(5).","DOI":"10.3390\/ijms17050683"},{"key":"5394_CR33","doi-asserted-by":"publisher","unstructured":"Deckert M, Montesinos-Rongen M, Brunn A, Siebert R. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2014;127(2):175\u201388. https:\/\/doi.org\/10.1007\/s00401-013-1202-x . Epub 2013 Nov 16.","DOI":"10.1007\/s00401-013-1202-x"},{"issue":"6","key":"5394_CR34","first-page":"3333","volume":"35","author":"DH Lim","year":"2015","unstructured":"Lim DH, Kim WS, Kim SJ, Yoo HY, Ko YH. Microarray gene-expression profiling analysis comparing PCNSL and non-CNS diffuse large B-cell lymphoma. Anticancer Res. 2015;35(6):3333\u201340.","journal-title":"Anticancer Res"},{"issue":"5","key":"5394_CR35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.21037\/jgo.2016.06.10","volume":"7","author":"CM Kelly","year":"2016","unstructured":"Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol. 2016;7(5):750\u201362.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"5394_CR36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, et al. MYC drives progression of small cell lung Cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell. 2017;31(2):270\u201385.","journal-title":"Cancer Cell"},{"issue":"3","key":"5394_CR37","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/1535-7163.MCT-11-0184","volume":"11","author":"KE Hook","year":"2012","unstructured":"Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11(3):710\u20139.","journal-title":"Mol Cancer Ther"},{"key":"5394_CR38","doi-asserted-by":"publisher","unstructured":"Posternak V, Cole MD. Strategically targeting MYC in cancer. F1000Res. 2016;5. https:\/\/doi.org\/10.12688\/f1000research.7879.1 .","DOI":"10.12688\/f1000research.7879.1"},{"key":"5394_CR39","doi-asserted-by":"crossref","unstructured":"Sabnis HS, Somasagara RR, Bunting KD. Targeting MYC dependence by metabolic inhibitors in Cancer. Genes (Basel). 2017;8(4).","DOI":"10.3390\/genes8040114"},{"issue":"9","key":"5394_CR40","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-13-2617","volume":"20","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20(9):2433\u201344.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5394_CR41","first-page":"3365","volume":"34","author":"H Saito","year":"2014","unstructured":"Saito H, Ando S, Morishita N, Lee KM, Dator D, Dy D, Shigemura K, Adhim Z, Nibu K, Fujisawa M, et al. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. Anticancer Res. 2014;34(7):3365\u201370.","journal-title":"Anticancer Res"},{"issue":"1","key":"5394_CR42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.30425","volume":"140","author":"NC Synnott","year":"2017","unstructured":"Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234\u201346.","journal-title":"Int J Cancer"},{"issue":"17","key":"5394_CR43","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011;17(17):5638\u201348.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5394_CR44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1158\/0008-5472.CAN-14-2405","volume":"75","author":"AE Vilgelm","year":"2015","unstructured":"Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res. 2015;75(1):181\u201393.","journal-title":"Cancer Res"},{"issue":"3","key":"5394_CR45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1158\/1541-7786.MCR-14-0277-T","volume":"13","author":"Z Li","year":"2015","unstructured":"Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, Huang J. p53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res. 2015;13(3):584\u201391.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"5394_CR46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/joim.12336","volume":"277","author":"J Zawacka-Pankau","year":"2015","unstructured":"Zawacka-Pankau J, Selivanova G. Pharmacological reactivation of p53 as a strategy to treat cancer. J Intern Med. 2015;277(2):248\u201359.","journal-title":"J Intern Med"},{"issue":"22","key":"5394_CR47","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1007\/s00018-017-2575-0","volume":"74","author":"D Zhao","year":"2017","unstructured":"Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH. Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci. 2017;74(22):4171\u201387.","journal-title":"Cell Mol Life Sci"},{"issue":"6132","key":"5394_CR48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","volume":"340","author":"D Rohle","year":"2013","unstructured":"Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626\u201330.","journal-title":"Science"},{"issue":"9","key":"5394_CR49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/14656566.2016.1176146","volume":"17","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259\u201370.","journal-title":"Expert Opin Pharmacother"},{"key":"5394_CR50","doi-asserted-by":"publisher","unstructured":"Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375). https:\/\/doi.org\/10.1126\/scitranslmed.aal2463 .","DOI":"10.1126\/scitranslmed.aal2463"},{"issue":"3","key":"5394_CR51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"issue":"2","key":"5394_CR52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"key":"5394_CR53","unstructured":"DGIdb - The Drug Gene Interaction Database [ http:\/\/www.dgidb.org\/search_interactions ]. Accessed 14 Apr 2018."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5394-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5394-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5394-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T01:02:48Z","timestamp":1606611768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5394-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5394"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5394-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"15 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local ethics committee (Ethikkommission der Landes\u00e4rztekammer Baden-W\u00fcrttemberg, F-2010-030) and undertaken in accordance with national law, institutional ethical standards, and the Helsinki Declaration. Written informed consent was provided either by the patient or a legally competent next of kin prior to the first study specific intervention.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As part of the written informed consent patients were informed about possible publication of the results of this investigation. Their consent to the study included a consent to publication of data while preserving anonymity. All presented data \/ images are selected without compromising the patients\u2019 anonymity. Specific consent is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Saskia Biskup is a co-founder of CeGaT GmbH (T\u00fcbingen, Germany). Dirk Hadaschik, Florian Battke and Dennis D\u00f6cker are currently employed by CeGaT GmbH (T\u00fcbingen, Germany) All other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"192"}}